Retatrutide
The most powerful weight loss peptide studied to date — it works by sending three separate signals to your body at once: eat less, burn more fat, and use energy more efficiently. At low "microdoses" it quietly reduces food cravings and supports mood, focus, and modest weight loss without the side effects of higher doses.
What is Retatrutide?
Retatrutide is a next-generation peptide developed by Eli Lilly that simultaneously activates three gut-hormone receptors: GLP-1 (appetite regulation and blood sugar), GIP (metabolic efficiency), and glucagon (fat burning and energy expenditure). This triple-action mechanism distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP), making it the most potent metabolic compound studied to date.
At microdose levels (0.5–2mg weekly), retatrutide delivers meaningful benefits — quieting food noise, improving cognition, supporting mood, and producing modest weight loss — with a significantly more tolerable side effect profile than standard titration.
Why Microdose?
Sub-standard doses unlock the cognitive, behavioral, and metabolic benefits of retatrutide without the aggressive weight loss trajectory — ideal for those with modest goals or high side-effect sensitivity.
Microdosing is a strong fit if you:
- /Want to lose 10–25 lbs rather than a dramatic transformation
- /Are primarily seeking food noise reduction, cognitive clarity, or addiction-adjacent benefits
- /Are sensitive to GI side effects at standard doses
- /Want a maintenance protocol after reaching your goal weight
Dose Calculator
Slide to your desired dose or enter your vial details manually. Defaults to a standard 24mg / 3mL vial (8 mg/mL). Edit mg or mL fields to match your actual vial.
= 8.00 mg/mL
Always verify the concentration printed on your specific vial — compounded preparations can vary. Use a 0.5 mL or 1 mL syringe for accuracy at low volumes.
Common Protocol Schedules
Community-derived from Phase 2 trial data and clinical user reports. No FDA-validated microdose protocol exists. All doses are subcutaneous injection.
| Protocol | Weekly Total | Frequency | Best For |
|---|---|---|---|
| Ultra-low start | 0.5 mg | Once weekly | Sensitivity testing, first 2–4 weeks |
| Standard micro | 1.0 mg | Once weekly | Food noise, mild weight loss, cognitive benefits |
| Split micro | 2.0 mg | 0.5–1 mg twice weekly | Steadier blood levels, reduced nausea peaks |
| Maintenance micro | 1–2 mg | 1 mg twice weekly | Post-goal weight maintenance |
| Escalation entry | 2 → 4 mg | Weekly, +2mg every 4 wks | Bridging to standard dosing if more loss desired |
Highlighted rows = most common entry protocols. The 1mg flat dose produced ~8.7% body weight loss at 48 weeks in Phase 2 — roughly 17–20 lbs for a 200 lb person.
Standard Dosing Reference
Full titration range based on a 24mg / 3mL vial (8 mg/mL) using a U-100 insulin syringe. On a U-100 syringe: 1 unit = 0.01 mL = 0.08 mg.
| Dose | Units (U-100) | Volume (mL) | Doses / Vial | Typical Use |
|---|---|---|---|---|
| 0.5 mg | 6.25 units | 0.063 mL | 48 doses | Ultra-low / sensitivity |
| 1.0 mg | 12.5 units | 0.125 mL | 24 doses | Standard microdose |
| 2.0 mg | 25 units | 0.25 mL | 12 doses | Split micro / escalation |
| 4.0 mg | 50 units | 0.50 mL | 6 doses | Low standard |
| 8.0 mg | 100 units | 1.0 mL | 3 doses | Mid standard |
| 12.0 mg | 150 units | 1.5 mL | 2 doses | High / trial max |
Highlighted rows = typical microdosing range. Use the calculator above to compute units for any custom concentration.
Benefits Beyond Weight Loss
Effects reported across both microdose and standard-dose protocols — many beginning within the first 1–2 weeks.
GLP-1 and GIP receptor activation in the brain's reward centers dramatically reduces the constant background stream of food-focused thoughts — intrusive cravings, meal bargaining, compulsive snacking urges — without willpower effort. Most users report this within 1–2 weeks, even at microdose levels.
As systemic inflammation decreases and glucose metabolism normalizes, users commonly report reduced brain fog, sharper focus, and improved memory. Preclinical studies show neurotrophic and neuroprotective effects — retatrutide outperforms mono- and dual agonists in reducing neuroinflammation markers.
Emerging research across GLP-1 drugs shows meaningful reductions in alcohol consumption, smoking urges, and other addictive behaviors. The mechanism involves GLP-1 receptors in the dopamine reward pathway — blunting the compulsive pull of substances the same way it quiets food noise.
Preclinical studies demonstrate antidepressant and anxiolytic effects via GLP-1 receptor activation. The SELECT trial (n=17,604) found no increase in depression or psychiatric adverse events versus placebo over 5 years. Many users report improved confidence and emotional steadiness.
Well-documented improvements in blood sugar control, insulin sensitivity, triglycerides, and blood pressure. GLP-1 medications reduce cardiovascular event risk even in people without diabetes. Retatrutide's glucagon component adds enhanced fat oxidation on top of these established benefits.
In Phase 2 trials, retatrutide 8mg users showed significantly higher SF-36 quality-of-life scores versus placebo at 24 and 48 weeks — spanning physical function, reduced hunger perception, and self-reported disinhibition around eating.
Phase 3 TRIUMPH-4 trial data found substantial relief from osteoarthritis knee pain alongside weight loss. Reduced fat mass, lower systemic inflammation, and direct anti-inflammatory receptor signaling all contribute independently of weight change.
Phase 2a trial data published in Nature Medicine showed meaningful improvement in metabolic-dysfunction-associated steatotic liver disease (MASLD), with reduced liver fat and improved metabolic markers — positioning retatrutide as a potential treatment for fatty liver disease.
Common Questions
Side Effects to Monitor
- /Nausea (most common, especially first 24–48 hrs post-injection)
- /Vomiting
- /Diarrhea or constipation
- /Reduced appetite (intended — monitor nutrition intake)
- /Injection site reactions (redness, mild swelling)
- /Fatigue (early weeks, usually transient)
- /Anxiety or mood changes during dose escalation
Most GI side effects peak in the first 24–48 hours after injection and resolve as the body adapts. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods around injection day reduces severity. If anxiety or mood changes feel persistent, consult your provider.
Order Your Retatrutide Protocol
USA-formulated, lab-verified. Includes dosing guidance from our clinical team.
Order Now